Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


H5N1 Infection (Avian Influenza)-Pipeline Review, H1 2015

H5N1 Infection (Avian Influenza)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

H5N1 Infection (Avian Influenza)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'H5N1 Infection (Avian Influenza)-Pipeline Review, H1 2015', provides an overview of the H5N1 Infection (Avian Influenza)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

H5N1 Infection (Avian Influenza) Overview 10

Therapeutics Development 11

Pipeline Products for H5N1 Infection (Avian Influenza)-Overview 11

Pipeline Products for H5N1 Infection (Avian Influenza)-Comparative Analysis 12

H5N1 Infection (Avian Influenza)-Therapeutics under Development by Companies 13

H5N1 Infection (Avian Influenza)-Therapeutics under Investigation by Universities/Institutes 18

H5N1 Infection (Avian Influenza)-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

H5N1 Infection (Avian Influenza)-Products under Development by Companies 22

H5N1 Infection (Avian Influenza)-Products under Investigation by Universities/Institutes 27

H5N1 Infection (Avian Influenza)-Companies Involved in Therapeutics Development 28

Akshaya Bio Inc. 28

AlphaVax, Inc. 29

Antigen Express, Inc. 30

Aphios Corporation 31

Aprogen, Inc. 32

BioDiem Ltd 33

CEL-SCI Corporation 34

Cocrystal Pharma, Inc. 35

Daiichi Sankyo Company, Limited 36

Emergent BioSolutions Inc. 37

Gemmus Pharma Inc. 38

GlaxoSmithKline Plc 39

Green Cross Corporation 40

Hemispherx Biopharma, Inc. 41

iBio, Inc. 42

Immunovaccine, Inc. 43

Inovio Pharmaceuticals, Inc. 44

Johnson & Johnson 45

Kineta, Inc. 46

Medicago Inc. 47

Medigen Biotechnology Corporation 48

Microgen Scientific Industrial Company for Immunobiological Medicines 49

Myelo Therapeutics GmbH 50

NanoBio Corporation 51

Nanotherapeutics, Inc. 52

NanoViricides, Inc. 53

NewLink Genetics Corporation 54

Novartis AG 55

OPKO Health, Inc. 56

PaxVax 57

PDS Biotechnology Corporation 58

PeptiDream Inc. 59

Protein Sciences Corporation 60

REPLICor Inc. 61

SIGA Technologies, Inc. 62

Sirnaomics, Inc. 63

Takeda Pharmaceutical Company Limited 64

TechnoVax, Inc. 65

Vaxart, Inc. 66

Vaxin, Inc. 67

Vaxine Pty Ltd 68

VaxInnate Corporation 69

H5N1 Infection (Avian Influenza)-Therapeutics Assessment 70

Assessment by Monotherapy Products 70

Assessment by Combination Products 71

Assessment by Target 72

Assessment by Mechanism of Action 74

Assessment by Route of Administration 76

Assessment by Molecule Type 78

Drug Profiles 80

A-06-Drug Profile 80

AE-443p-Drug Profile 81

Alferon LDO-Drug Profile 83

APP-0205-Drug Profile 85

APP-309-Drug Profile 86

AT-301-Drug Profile 87

CEL-1000-Drug Profile 88

DP-C005-Drug Profile 90

FBF-001-Drug Profile 91

FDX-000-Drug Profile 92

Gamma-Flu-Drug Profile 93

GP-1001-Drug Profile 94

GP-1002-Drug Profile 95

GP-1681-Drug Profile 96

GREFLU/VIE-Drug Profile 98

HAI-05-Drug Profile 99

iHA-24-Drug Profile 100

Influ-nRNA-Drug Profile 101

influenza (strain H5N1, H1N1) vaccine-Drug Profile 102

influenza [strain A/H5N1] vaccine-Drug Profile 103

influenza [strain H5N1, H1N1] vaccine-Drug Profile 104

influenza [strain H5N1, H7N2, H9N2] virus like particle vaccine-Drug Profile 105

influenza [strain H5N1] (split virion) vaccine-Drug Profile 106

influenza [strain H5N1] vaccine-Drug Profile 107

influenza [strain H5N1] vaccine-Drug Profile 108

influenza [strain H5N1] vaccine-Drug Profile 109

influenza [strain H5N1] vaccine-Drug Profile 110

influenza [strain H5N1] vaccine-Drug Profile 111

influenza [strain H5N1] vaccine-Drug Profile 113

influenza [strain H5N1] vaccine-Drug Profile 114

influenza [strain H5N1] vaccine-Drug Profile 115

influenza [strain H5N1] vaccine-Drug Profile 116

influenza [strain H5N1] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant-Drug Profile 117

influenza A vaccine-Drug Profile 119

influenza vaccine-Drug Profile 120

influenza vaccine-Drug Profile 121

influenza vaccine-Drug Profile 122

influenza vaccine-Drug Profile 124

influezna [strain H5N1] virus like particles vaccine-Drug Profile 125

Innate Immune Adjuvants-Drug Profile 127

INO-3401-Drug Profile 128

INO-3510-Drug Profile 129

INO-3605-Drug Profile 130

INO-3609-Drug Profile 131

IPS-07 series-Drug Profile 132

JNJ-872-Drug Profile 133

KD-295-Drug Profile 135

KIB-PCI-Drug Profile 136

MG-1109-Drug Profile 137

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza-Drug Profile 139

MVAH-5HA-Drug Profile 140

Myelo-001-Drug Profile 141

NVINF-1-Drug Profile 142

NVINF-2-Drug Profile 144

OrniFlu-Drug Profile 145

PanBlok-Drug Profile 146

PDS-0102-Drug Profile 148

PNSIA-28-Drug Profile 149

PNSIA-49-Drug Profile 150

PXVX-0103-Drug Profile 151

REP-9-Drug Profile 153

rintatolimod-Drug Profile 154

Small Molecule for Influenza Virus-Drug Profile 156

Small Molecules to Activate Sirtuin for Influenza-Drug Profile 157

Small Molecules to Inhibit Endonuclease for Flu-Drug Profile 158

STP-702-Drug Profile 159

Synthetic Peptides for Influenza, HSV and HIV Infections-Drug Profile 160

TVX-003-Drug Profile 161

VAX-161-Drug Profile 162

VH-244-Drug Profile 163

H5N1 Infection (Avian Influenza)-Recent Pipeline Updates 165

H5N1 Infection (Avian Influenza)-Dormant Projects 186

H5N1 Infection (Avian Influenza)-Discontinued Products 191

H5N1 Infection (Avian Influenza)-Product Development Milestones 192

Featured News & Press Releases 192

Appendix 200

Methodology 200

Coverage 200

Secondary Research 200

Primary Research 200

Expert Panel Validation 200

Contact Us 200

Disclaimer 201

List of Tables

Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2015 16

Number of Products under Development for H5N1 Infection (Avian Influenza)-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 19

Number of Products under Development by Companies, H1 2015 (Contd..1) 20

Number of Products under Development by Companies, H1 2015 (Contd..2) 21

Number of Products under Development by Companies, H1 2015 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Development by Companies, H1 2015 (Contd..4) 31

Products under Investigation by Universities/Institutes, H1 2015 32

H5N1 Infection (Avian Influenza)-Pipeline by Akshaya Bio Inc., H1 2015 33

H5N1 Infection (Avian Influenza)-Pipeline by AlphaVax, Inc., H1 2015 34

H5N1 Infection (Avian Influenza)-Pipeline by Antigen Express, Inc., H1 2015 35

H5N1 Infection (Avian Influenza)-Pipeline by Aphios Corporation, H1 2015 36

H5N1 Infection (Avian Influenza)-Pipeline by Aprogen, Inc., H1 2015 37

H5N1 Infection (Avian Influenza)-Pipeline by BioDiem Ltd, H1 2015 38

H5N1 Infection (Avian Influenza)-Pipeline by CEL-SCI Corporation, H1 2015 39

H5N1 Infection (Avian Influenza)-Pipeline by Cocrystal Pharma, Inc., H1 2015 40

H5N1 Infection (Avian Influenza)-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 41

H5N1 Infection (Avian Influenza)-Pipeline by Emergent BioSolutions Inc., H1 2015 42

H5N1 Infection (Avian Influenza)-Pipeline by Gemmus Pharma Inc., H1 2015 43

H5N1 Infection (Avian Influenza)-Pipeline by GlaxoSmithKline Plc, H1 2015 44

H5N1 Infection (Avian Influenza)-Pipeline by Green Cross Corporation, H1 2015 45

H5N1 Infection (Avian Influenza)-Pipeline by Hemispherx Biopharma, Inc., H1 2015 46

H5N1 Infection (Avian Influenza)-Pipeline by iBio, Inc., H1 2015 47

H5N1 Infection (Avian Influenza)-Pipeline by Immunovaccine, Inc., H1 2015 48

H5N1 Infection (Avian Influenza)-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 49

H5N1 Infection (Avian Influenza)-Pipeline by Johnson & Johnson, H1 2015 50

H5N1 Infection (Avian Influenza)-Pipeline by Kineta, Inc., H1 2015 51

H5N1 Infection (Avian Influenza)-Pipeline by Medicago Inc., H1 2015 52

H5N1 Infection (Avian Influenza)-Pipeline by Medigen Biotechnology Corporation, H1 2015 53

H5N1 Infection (Avian Influenza)-Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H1 2015 54

H5N1 Infection (Avian Influenza)-Pipeline by Myelo Therapeutics GmbH, H1 2015 55

H5N1 Infection (Avian Influenza)-Pipeline by NanoBio Corporation, H1 2015 56

H5N1 Infection (Avian Influenza)-Pipeline by Nanotherapeutics, Inc., H1 2015 57

H5N1 Infection (Avian Influenza)-Pipeline by NanoViricides, Inc., H1 2015 58

H5N1 Infection (Avian Influenza)-Pipeline by NewLink Genetics Corporation, H1 2015 59

H5N1 Infection (Avian Influenza)-Pipeline by Novartis AG, H1 2015 60

H5N1 Infection (Avian Influenza)-Pipeline by OPKO Health, Inc., H1 2015 61

H5N1 Infection (Avian Influenza)-Pipeline by PaxVax, H1 2015 62

H5N1 Infection (Avian Influenza)-Pipeline by PDS Biotechnology Corporation, H1 2015 63

H5N1 Infection (Avian Influenza)-Pipeline by PeptiDream Inc., H1 2015 64

H5N1 Infection (Avian Influenza)-Pipeline by Protein Sciences Corporation, H1 2015 65

H5N1 Infection (Avian Influenza)-Pipeline by REPLICor Inc., H1 2015 66

H5N1 Infection (Avian Influenza)-Pipeline by SIGA Technologies, Inc., H1 2015 67

H5N1 Infection (Avian Influenza)-Pipeline by Sirnaomics, Inc., H1 2015 68

H5N1 Infection (Avian Influenza)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 69

H5N1 Infection (Avian Influenza)-Pipeline by TechnoVax, Inc., H1 2015 70

H5N1 Infection (Avian Influenza)-Pipeline by Vaxart, Inc., H1 2015 71

H5N1 Infection (Avian Influenza)-Pipeline by Vaxin, Inc., H1 2015 72

H5N1 Infection (Avian Influenza)-Pipeline by Vaxine Pty Ltd, H1 2015 73

H5N1 Infection (Avian Influenza)-Pipeline by VaxInnate Corporation, H1 2015 74

Assessment by Monotherapy Products, H1 2015 75

Assessment by Combination Products, H1 2015 76

Number of Products by Stage and Target, H1 2015 78

Number of Products by Stage and Mechanism of Action, H1 2015 80

Number of Products by Stage and Route of Administration, H1 2015 82

Number of Products by Stage and Molecule Type, H1 2015 84

H5N1 Infection (Avian Influenza) Therapeutics-Recent Pipeline Updates, H1 2015 170

H5N1 Infection (Avian Influenza)-Dormant Projects, H1 2015 191

H5N1 Infection (Avian Influenza)-Dormant Projects (Contd..1), H1 2015 192

H5N1 Infection (Avian Influenza)-Dormant Projects (Contd..2), H1 2015 193

H5N1 Infection (Avian Influenza)-Dormant Projects (Contd..3), H1 2015 194

H5N1 Infection (Avian Influenza)-Dormant Projects (Contd..4), H1 2015 195

H5N1 Infection (Avian Influenza)-Discontinued Products, H1 2015 196

List of Figures

Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2015 16

Number of Products under Development for H5N1 Infection (Avian Influenza)-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Products, H1 2015 26

Assessment by Monotherapy Products, H1 2015 75

Number of Products by Top 10 Targets, H1 2015 77

Number of Products by Stage and Top 10 Targets, H1 2015 77

Number of Products by Top 10 Mechanism of Actions, H1 2015 79

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 79

Number of Products by Top 10 Routes of Administration, H1 2015 81

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 81

Number of Products by Top 10 Molecule Types, H1 2015 83

Number of Products by Stage and Top 10 Molecule Types, H1 2015 83

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Akshaya Bio Inc.

AlphaVax, Inc.

Antigen Express, Inc.

Aphios Corporation

Aprogen, Inc.

BioDiem Ltd

CEL-SCI Corporation

Cocrystal Pharma, Inc.

Daiichi Sankyo Company, Limited

Emergent BioSolutions Inc.

Gemmus Pharma Inc.

GlaxoSmithKline Plc

Green Cross Corporation

Hemispherx Biopharma, Inc.

iBio, Inc.

Immunovaccine, Inc.

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Kineta, Inc.

Medicago Inc.

Medigen Biotechnology Corporation

Microgen Scientific Industrial Company for Immunobiological Medicines

Myelo Therapeutics GmbH

NanoBio Corporation

Nanotherapeutics, Inc.

NanoViricides, Inc.

NewLink Genetics Corporation

Novartis AG

OPKO Health, Inc.

PaxVax

PDS Biotechnology Corporation

PeptiDream Inc.

Protein Sciences Corporation

REPLICor Inc.

SIGA Technologies, Inc.

Sirnaomics, Inc.

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

Vaxart, Inc.

Vaxin, Inc.

Vaxine Pty Ltd

VaxInnate Corporation

H5N1 Infection (Avian Influenza) Therapeutic Products under Development, Key Players in H5N1 Infection (Avian Influenza) Therapeutics, H5N1 Infection (Avian Influenza) Pipeline Overview, H5N1 Infection (Avian Influenza) Pipeline, H5N1 Infection (Avian Influenza) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com